← All trials
NCT03541174
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 18, 2018
- Primary completion
- Feb 8, 2021
- Completion date
- Feb 8, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 600
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Idorsia Pharmaceuticals Ltd.Lead sponsor
- Janssen Pharmaceutica NVCollaborator
- Idorsia Pharmaceuticals Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.